PRL, prolactin, 5617

N. diseases: 506; N. variants: 3
Disease: Prostate carcinoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 AlteredExpression disease BEFREE Low preoperative PRL levels predict the risk of non-organ confined PCa in clinically localized disease. 30763940 2019
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 AlteredExpression disease BEFREE T and/or PRL increased CPD expression in several pCa but not benign cell lines. 24615730 2014
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE Prolactin (PRL), a potent growth stimulator of the mammary epithelium, has been suggested to be a factor contributing to the development and progression of breast and prostate cancer. 21954059 2011
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE Prolactin in breast and prostate cancer: molecular and genetic perspectives. 21524385 2011
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE These findings provide new insight into the molecular and cellular targets by which locally produced prolactin could contribute to prostate cancer initiation and progression. 21971318 2011
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 AlteredExpression disease BEFREE This study identifies PRL receptor/Stat5 as a unique pathway, initiating prostate tumorogenesis by altering basal-/stem-like cell subpopulations, and strongly supports the importance of further developing strategies to target locally overexpressed PRL in human prostate cancer. 20699217 2010
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 AlteredExpression disease BEFREE Prolactin protein expression and constitutive activation of Stat5a/b are associated with high histologic grade of clinical prostate cancer. 18316550 2008
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE The study also provides support for the use of Prl receptor antagonists or other therapeutic strategies to block the Prl-Janus kinase-2-Stat5 signaling pathway in advanced prostate cancer. 17412813 2007
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 AlteredExpression disease BEFREE We next examined the effect on pump activity of prolactin, an important mediator of cell proliferation in prostate cancer. 15672465 2004
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 AlteredExpression disease BEFREE Finally, Prl protein was locally expressed in the epithelium of 54% of 80 human prostate cancer specimens with positive correlation with high Gleason scores and activation of Stat5. 15256446 2004
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE Using an adenovirus transfer vector to achieve high efficiency 23-kDa and 16-kDa PRL transfection in DU145 and PC-3 human prostate carcinoma cell lines, we demonstrated that expression of 16-kDa PRL in the prostate cancer cells markedly reduced their ability to form tumors in a xenograft animal model. 12543792 2003
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE The trophic effects of exogenous hGH, hPL, and hPRL were investigated by cell proliferation assays (WST-I) in prostatic primary cell cultures and PCa cell lines. hGH significantly (p < 0.005) increased cell proliferation up to 138+/-3.2% (1 nM hGH), while hPL and hPRL revealed only moderate effects. 10363793 1999
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE In this report we establish the role of prolactin in the regulation of mAAT in two prostate cancer cell lines, LNCaP and PC-3. 9099897 1997